OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
30/11/2025
Voltar para busca
Dado oficial do USPTO
ACTINEER
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
30
Atualização mais recente
03/04/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
1, 5, 10, 42, 44
Data de depósito
08/02/2024
Data de registro
01/04/2025
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
01/04/2025
Última transação
03/04/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
99
Localização do titular
DE
Examinador
FRENCH, CURTIS W
Unidade examinadora
M60
Localização atual
FILE REPOSITORY (FRANCONIA)
Descrição da marca
The mark consists of the term ACTINEER is stylized font with a design of a stylized ribbon to the left of the wording.
Titulares e representantes
Titulares
I. S. (pessoa física)
Representantes
Kari Moyer-Henry Lewis Kohn & Walker LLP
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 10Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemical substanceschemical materials and chemical preparations for use in the manufacture of medical products; chemical substanceschemical materials and chemical preparations for use in the manufacture of radiopharmaceutical products; chemical raw materialsin particular actinium-225 radiochemicalfor the formulation of radiopharmaceutical products; chemical raw materialsin particular bismuth-213for the formulation of radiopharmaceutical products
Classe 5
Radiopharmaceutical diagnostic preparations for medical purposes; radiopharmaceutical diagnostic preparations for pharmaceutical purposes; radiopharmaceutical therapeutic preparations for medical purposes; radiopharmaceutical therapeutic preparations for pharmaceutical purposesin particular radiopharmaceutical preparations for endo-radionuclide therapybrachytherapypositron emission tomographysingle photon emission computed tomographytarget radionuclide therapy and peptide receptor radionuclide therapy; radiopharmaceutical preparationsin particular actinium-containing radiopharmaceutical products in GMP quality; radiopharmaceutical preparationsin particular bismuth-containing radiopharmaceutical products in GMP quality; radiopharmaceutical preparations for use in oncologyin particular radiopharmaceuticals containing radioisotopesin particular actinium-225; radiopharmaceutical preparations for use in oncologyin particular radiopharmaceuticals containing radioisotopesin particular bismuth-213; radiopharmaceuticals containing medical radioisotopes with longer half-livesin particular actinium-225 for the treatment of tumour diseases; radiopharmaceuticals containing medical radioisotopes with longer half-livesin particular bismuth-213 for the treatment of tumour diseases; target radiopharmaceuticals containing a target moleculein particular peptidedepending on the indicationa medical radioactive isotope; target radiopharmaceuticals containing a target moleculein particular an antibody dependingon the indicationa medical radioactive isotope; radiopharmaceuticals containing actinium-225 and its complexes; radiopharmaceuticals containing bismuth-213 and its complexes
Classe 10
Medical instrumentsapparatus and containers for the production of radiopharmaceutical preparationsnamely sample preparation devices automatically or manually operated in particular for the production of actinium-225 in GMP quality; medical instrumentsapparatus and containers for the production of radiopharmaceutical preparationsnamely sample preparation devices automatically or manually operated in particular for the production of bismuth-213 in GMP quality; controlregulation and measuring apparatus as parts of medical instrumentsapparatus and containersin particular devices containing fluidic processing components as valvessmall vessels (5-500 ml) and purification columns for the production of a radiotherapeutic or radiodiagnostic substancein particular for the production of actinium-225 in GMP quality; controlregulation and measuring apparatus as parts of medical instrumentsapparatus and containers included in this classin particular devices containing fluidic processing components as valvessmall vessels (5-500 ml) and purification columns for the production of a radiotherapeutic or radiodiagnostic substancein particular for the production of bismuth-213 in GMP quality; radionuclide generator for radiopharmaceutical purpose
Classe 42
Scientific and technological services and research relating to the use of actinium-225in particular medical and pharmacological research services relating to the use of actinium-225; scientific and technological services and research relating to the use of bismuth-213in particular medical and pharmacological research services relating to the use of bismuth-213; scientific and technological services and research relating to the use of other alpha emittersin particular medical and pharmacological research services relating to the use of other alpha emitters
Classe 44
Medical servicesin particular medical services relating to radiotherapeutic and radiodiagnostic oncologycardiologyangiologyneuroradiologynuclear medicine and brachytherapiesnamely intercavitaryinterstitial and intravascular brachytherapyradionuclide labellingPET and SPECT scanning and radionuclide therapypeptide receptor radionuclide therapypersonal nuclear medicine and precision oncology; medical services for theranostics in the field of precision oncology
Publicações
Histórico de despachos e eventos da marca no USPTO.
30 publicações encontradas
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
12/11/2025
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
12/11/2025
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
31/10/2025
FICS
FINAL DISPOSITION NOTICE SENT TO IB
15/10/2025
FIMP
FINAL DISPOSITION PROCESSED
14/10/2025
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
02/07/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
01/04/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
01/04/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/02/2025
PUBO
PUBLISHED FOR OPPOSITION
11/02/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/02/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
21/01/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
30/12/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
30/12/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
30/12/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
18/12/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
18/12/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
18/12/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
18/12/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
18/12/2024
RFNT
REFUSAL PROCESSED BY IB
30/09/2024
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
11/09/2024
RFRR
REFUSAL PROCESSED BY MPU
11/09/2024
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
09/09/2024
CNRT
NON-FINAL ACTION WRITTEN
08/09/2024
DOCK
ASSIGNED TO EXAMINER
02/09/2024
MAFR
APPLICATION FILING RECEIPT MAILED
20/06/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
20/06/2024
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
13/06/2024
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ACTINEER ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.